Zynerba Pharmaceuticals, Inc. (ZYNE) saw its loss widen to $7.26 million, or $0.60 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $4.28 million, or $0.49 a share.

The company has not recorded any revenues for the current quarter. However, it has reported a revenue of $0.01 million for the previous year period.

Operating loss for the quarter was $7.70 million, compared with an operating loss of $4.24 million in the previous year period.

"This quarter, we were very pleased to have surpassed target enrollment in both the STAR 1 and STOP trials for ZYN002 in adult epilepsy and adult osteoarthritis patients, respectively, which we believe indicates strong patient and physician interest in these indications for ZYN002," said Armando Anido, chairman and chief executive officer. "We are swiftly advancing our Phase 2 programs for ZYN002 and expect to announce top-line results for the STAR 1 trial first and then the STOP trial in the July/August timeframe, followed by top-line results from the FAB-C study in pediatric Fragile X syndrome patients later in the third quarter. We have also made important progress toward initiating our Phase 1 program for ZYN001, a pro-drug THC patch, which we expect to start by the end of the second quarter of 2017."